Advertisement
Canada markets closed

  • S&P/TSX

    22,290.62
    +31.15 (+0.14%)
     

  • S&P 500

    5,187.70
    +6.96 (+0.13%)
     

  • DOW

    38,884.26
    +31.99 (+0.08%)
     

  • CAD/USD

    0.7273
    -0.0013 (-0.18%)
     

  • CRUDE OIL

    78.04
    -0.34 (-0.43%)
     

  • Bitcoin CAD

    86,176.06
    -1,339.34 (-1.53%)
     

  • CMC Crypto 200

    1,301.20
    -63.92 (-4.68%)
     

  • GOLD FUTURES

    2,323.70
    -0.50 (-0.02%)
     

  • RUSSELL 2000

    2,064.65
    +3.97 (+0.19%)
     

  • 10-Yr Bond

    4.4630
    -0.0260 (-0.58%)
     

  • NASDAQ futures

    18,199.75
    +0.25 (+0.00%)
     

  • VOLATILITY

    13.23
    -0.26 (-1.93%)
     

  • FTSE

    8,313.67
    +100.18 (+1.22%)
     

  • NIKKEI 225

    38,303.39
    -531.71 (-1.37%)
     

  • CAD/EUR

    0.6768
    -0.0003 (-0.04%)
     

Why Shares of Bellus Health Skyrocketed This Week

Jim Halley, The Motley Fool
·2 min read
Why Shares of Bellus Health Skyrocketed This Week

Shares of Bellus Health (NASDAQ: BLU) jumped 105.1% this week as of Thursday afternoon, according to data provided by S&P Global Market Intelligence. The company, which received a $2 billion buyout offer from GSK (formerly known as GlaxoSmithKline) (NYSE: GSK), closed at $7.06 last week and reached a new 52-week high at $14.50 on Tuesday. The attraction for GSK is camlipixant, Bellus' late-stage pipeline candidate to treat adults with refractory chronic cough (RCC).

Continue reading